Population Pharmacokinetics and Exposure-Response of Trametinib, a MEK inhibitor, in Patients with BRAF V600 mutation-positive melanoma

The purpose of this study was to characterize the pharmacokinetics of oral trametinib, a first in class MEK inhibitor, identify covariates, and describe the relationship between exposure and clinical effects in patients with BRAF V600 metastatic melanoma. Trametinib concentrations obtained in three clinical studies were included in the population pharmacokinetic analysis. Trametinib 2 mg once daily was […]

Read More
Topics:
Learn More
LinkedIn